Daniel Bradbury Sells 600 Shares of Illumina, Inc. (ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) Director Daniel Bradbury sold 600 shares of Illumina stock in a transaction that occurred on Tuesday, March 21st. The stock was sold at an average price of $163.56, for a total value of $98,136.00. Following the completion of the sale, the director now owns 17,065 shares in the company, valued at $2,791,151.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Daniel Bradbury also recently made the following trade(s):

  • On Friday, February 17th, Daniel Bradbury sold 600 shares of Illumina stock. The stock was sold at an average price of $162.80, for a total value of $97,680.00.
  • On Wednesday, January 4th, Daniel Bradbury sold 600 shares of Illumina stock. The stock was sold at an average price of $135.01, for a total value of $81,006.00.

Illumina, Inc. (NASDAQ:ILMN) opened at 170.58 on Monday. The stock has a market cap of $24.96 billion, a PE ratio of 55.56 and a beta of 0.79. The stock has a 50 day moving average price of $164.48 and a 200 day moving average price of $152.74. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $186.88.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, January 31st. The life sciences company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.03. Illumina had a return on equity of 22.89% and a net margin of 19.31%. The firm had revenue of $619 million for the quarter, compared to the consensus estimate of $612.50 million. During the same period in the prior year, the business posted $0.81 earnings per share. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. On average, analysts predict that Illumina, Inc. will post $3.64 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

TRADEMARK VIOLATION WARNING: This article was originally reported by Mideast Time and is the property of of Mideast Time. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.mideasttime.com/daniel-bradbury-sells-600-shares-of-illumina-inc-ilmn-stock/1589136.html.

Several large investors have recently modified their holdings of the company. Concert Wealth Management Inc. increased its stake in shares of Illumina by 2.9% in the third quarter. Concert Wealth Management Inc. now owns 1,732 shares of the life sciences company’s stock valued at $315,000 after buying an additional 48 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of Illumina by 0.6% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,421 shares of the life sciences company’s stock valued at $1,078,000 after buying an additional 48 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its stake in shares of Illumina by 2.0% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 3,771 shares of the life sciences company’s stock valued at $685,000 after buying an additional 73 shares during the last quarter. Stanford Investment Group Inc. increased its stake in shares of Illumina by 5.7% in the fourth quarter. Stanford Investment Group Inc. now owns 1,400 shares of the life sciences company’s stock valued at $179,000 after buying an additional 75 shares during the last quarter. Finally, Girard Securities Inc. increased its stake in shares of Illumina by 5.1% in the fourth quarter. Girard Securities Inc. now owns 2,065 shares of the life sciences company’s stock valued at $264,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 92.79% of the company’s stock.

ILMN has been the topic of a number of recent analyst reports. CL King upgraded Illumina from a “neutral” rating to a “buy” rating in a research report on Friday, January 6th. Vetr upgraded Illumina from a “buy” rating to a “strong-buy” rating and set a $148.34 price objective on the stock in a research report on Tuesday, January 3rd. Evercore ISI upgraded Illumina from a “hold” rating to a “buy” rating and set a $190.00 price objective on the stock in a research report on Monday, February 27th. Cowen and Company reiterated an “outperform” rating and issued a $150.00 price objective on shares of Illumina in a research report on Wednesday, January 11th. Finally, Bank of America Corp upgraded Illumina from a “neutral” rating to a “buy” rating and lifted their price target for the company from $145.00 to $175.00 in a research report on Tuesday, January 10th. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eleven have issued a buy rating to the company. Illumina currently has a consensus rating of “Hold” and a consensus target price of $158.93.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

5 Day Chart for NASDAQ:ILMN

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.